Finsbury Glover Hering Completes Merger and Buy-in and Announces Global Executive Leadership
Following their announcement on 7 July 2020, Finsbury, The Glover Park Group (GPG) and Hering Schuppener have completed their merger and management buy-in of 49.99 per cent of the combined business. The merger will create a pre-eminent global strategic communications and public affairs consultancy, operating from 18 offices with almost 700 consultants. WPP will remain a 50.01 per cent investor and Mark Read, CEO of WPP, will join the Board.
Over the past six months, the three firms have worked to integrate their operations and today announce global executive leadership teams, who will be charged with overseeing operations and driving growth across their regions.
Alexander Geiser serves as Global CEO and Regional CEO for Europe, Mike Feldman and Winnie Lerner as Regional Co-CEOs for North America and Faeth Birch as Regional CEO for the United Kingdom, Middle East and Asia. As previously announced, Carter Eskew and Roland Rudd are Co-Chairmen of the firm.
The merger of the three firms comes at a time when companies and organizations are navigating through an increasingly complex operating environment and balancing challenging social, political and economic dynamics. Finsbury Glover Hering will be a trusted partner to its clients, supporting their efforts to manage through these cross-currents and achieve their business goals. The combined entity will offer clients new reach across stakeholder audiences and geographies, allowing for fully-integrated communications campaigns.
Roland Rudd, Co-Chairman, said, “This is a great moment for Finsbury Glover Hering, we are all energised and excited by the opportunity to create a very special, owner-led firm and be an even better partner to our existing and new clients. We thank them for their support.”
“I am proud to have such a talented team leading our people across the world. I have worked with both Mike and Winnie for decades and have collaborated with Alex and Faeth on global projects over the years. The future of our global firm could not be in better hands,” said Carter Eskew, Co-Chairman.
Alexander Geiser, CEO, added: “We have received overwhelmingly positive feedback from clients and employees alike for this step. Both externally and internally, many have already experienced us as one firm. Now it has really become one firm – with a global brand, balance sheet and governance.”
About Finsbury Glover Hering
Finsbury Glover Hering is a new pre-eminent global strategic communications advisory firm, headquartered in New York City with almost 700 multidisciplinary experts across the world’s major financial, government, business and cultural centers. The company was formed through the merger of the leading strategic communications consultancies Finsbury, The Glover Park Group (GPG) and Hering Schuppener. The firm provides combined support in Business Transformation, Corporate Reputation & Leadership Strategies, Crisis & Issues Management, Government Relations & Policy and Advocacy as well as Transaction & Financial Communications, supported by research & insights, digital strategy, design and creative solutions.
Finsbury Glover Hering serves its global client base from offices in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Munich, New York, Riyadh, Shanghai, Singapore, Tokyo and Washington D.C.
Find more information visit www.fgh.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005217/en/
Contact information
Press contacts
USA
Ben Waldron
ben.waldron@fgh.com
+1 347 622 3740
UK
Dorothy Burwell
dorothy@fgh.com
+44 (20) 7251 3801
Europe
Dirk von Manikowsky
dirk.vonmanikowsky@fgh.com
+49 (211) 430 79 265
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom